Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24.
J Clin Pharmacol. 2014.
PMID: 24800725
Clinical Trial.
Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K.
Petersenn S, et al. Among authors: resendiz kh.
J Clin Pharmacol. 2012 Jul;52(7):1017-27. doi: 10.1177/0091270011408727. Epub 2011 Jun 14.
J Clin Pharmacol. 2012.
PMID: 21673137
Clinical Trial.
Item in Clipboard
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH.
Wolin EM, et al. Among authors: resendiz kh.
Cancer Chemother Pharmacol. 2013 Aug;72(2):387-95. doi: 10.1007/s00280-013-2202-1. Epub 2013 Jun 14.
Cancer Chemother Pharmacol. 2013.
PMID: 23765178
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite